Differences in Pre-Operative Mean Serum Concentration of Thyroid Stimulating Hormone (TSH) and Free Thyroxin (FT4) in Patients with Benign Thyroid Nodules and Thyroid Carcinoma at Sanglah General Hospital Denpasar

I Gusti Ayu Sri Mahendra Dewi, Desak Putu Gayatri Saraswati Seputra


Background: Thyroid Stimulating Hormone (TSH) and Free Thyroxin (FT4) concentration are currently highlighted in their relation to thyroid carcinoma development in thyroid nodule patients. This study aimed to identify the difference in the pre-operative mean serum concentration of TSH and FT4 in patients with benign thyroid nodules and thyroid carcinoma at Sanglah General Hospital Denpasar.

Methods: : This study was a case-control study that involved 110 patients with thyroid nodules who underwent thyroidectomy at Sanglah General Hospital from January until December 2019, whose specimens were examined histopathologically at the Anatomical Pathology Laboratory of Sanglah General Hospital. Cases were patients with thyroid carcinoma. Controls were patients with benign thyroid nodules. The data were collected from medical records.


Results: Most subjects in the thyroid carcinoma group were female (72.7%). The thyroid carcinoma group had a higher mean age at the time of thyroidectomy (47.33 ± 13.4) compared to the benign thyroid nodule group (46.07 ± 12.5) (p = 0.61). Significant difference was found regarding the nodule size between the two groups (p < 0.001). There were no significant differences in terms of nodule lateralization (p = 0.56) and the number of nodules (p = 0.58). Papillary thyroid carcinoma was the most common type of thyroid carcinoma (89.1%). A significantly higher pre-operative mean serum TSH concentration was found in cases (1.0 ± 0.23 IU/mL) compared to controls (0.8 ± 0.23 IU/mL) (p < 0.001). The pre-operative mean serum FT4 concentration was significantly lower in cases (1.1 ± 0.25 IU/mL) compared to controls (1.2 ± 0.22 IU/mL) (p = 0.006). The optimal TSH and FT4 cut-off values for thyroid carcinoma were > 1.0 IU/mL (61% sensitivity, 71% specificity) and < 1.1 IU/mL (61% sensitivity, 51% specificity), respectively


Conclusions: : Higher pre-operative mean TSH concentration and lower mean FT4 concentration were found in patients with thyroid carcinoma. There were statistically significant differences between patients with thyroid carcinoma and benign thyroid nodules in terms of these two laboratory parameters.



free thyroxin, thyroid carcinoma, thyroid nodule, thyroid-stimulating hormone

Full Text: View | Download

DOI: 10.33371/ijoc.v16i1.813

Article Metrics

Abstract View: 188,
PDF Download: 243


Haugen BR, Alexander EK, Bible KC, et al. 2015 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.

Nguyen QT, Lee EJ, Huang MG, et al. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits. 2015;8(1):30-40.

He L, Zeng T, Pu L, et al. Thyroid hormones, autoantibodies, ultrasonography, and clinical parameters for predicting thyroid cancer. Int J Endocrinol. 2016:1-12.

Popoveniuc G, Jonklaas J. Thyroid nodule. Med Clin North Am. 2012;96(2):329–49.

Rosario PW, Ward LS, Carvalho GA, et al. Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus. Arq Bras Endocrinol Metab. 2013;57(4):240-64.

Golbert L, Cristo AP, Faccin CS, et al. Serum TSH levels as a predictor of malignancy in thyroid nodules: A prospective study. PLoS ONE. 2017;12(11):1-12.

Rageh TM, Abdou AG, Elkhouly EA, et al. Preoperative significance of thyroglobulin, thyroid stimulating hormone and thyroglobulin antibody in differentiated papillary thyroid carcinoma. Int Surg J. 2019;6(12):4229-37.

Rianto BU, Wibowo AS, Herdini C. The difference in thyroid stimulating hormone levels between differentiated carcinoma and benign enlargement. Int Arch Otorhinolaryngol. 2020;24(1):74-9.

Ariannia A, Mehrjerdian M, Jalali M. Higher TSH level is associated with increased risk of malignancy in thyroid nodules. J Pioneer Med Sci.2020;9(1):8-10.

Fiore E, Rago T, Provenzale MA, et al. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer. 2009;16:1251–60.

Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab. 2012;97(4):1134–45.

Krashin E, Piekiełko-Witkowska A, Ellis M, Ashur-Fabian O. Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. Front Endocrinol. 2019;10(59):1-23.

Nayci AE, Arikan S, Akkus O, et al. Incidence of thyroid carcinoma among patients with hyper and hypothyroidism. Int Surg. 2017;102:328–333.

Bonnefond S, Davies TF. Thyroid cancer—risks and causes. Oncology & Hematology Review. 2014;10(2):144–51.

Gul K, Ozdemir D, Dirikoc A, et al. Are endogenously lower serum thyroid hormones, new predictors, for thyroid malignancy in addition to higher serum thyrotropin?. Endocr. 2010;37:253–60.


  • There are currently no refbacks.